List view / Grid view

Chronic lymphocytic leukaemia (CLL)



NICE asks Janssen to put ibrutinib forward for the CDF

1 June 2016 | By Victoria White, Digital Content Producer

The National Institute for Health and Care Excellence (NICE) has asked Janssen to set out a case for including its chronic lymphocytic leukaemia (CLL) drug ibrutinib (Imbruvica) in the Cancer Drugs Fund (CDF).